Go to deals
Healthcare

Clada Medical Devices has been acquired by Nordson Corporation - Medical

The private shareholders of Clada Medical Devices have sold the company to Nordson Corporation (Nasdaq: NDSN). Terms of the deal have not been disclosed.

Clada Medical Devices, an ISO 13485 certified company, provides the design and manufacture of catheter balloons and catheters to its customers. The company was founded in 2008 and is based in Galway, Ireland.

Clada will become part of the Nordson MEDICAL product line within Nordson’s Advanced Technology Systems segment. This acquisition builds on the company’s strategic objective to grow Nordson’s precision applications within the minimally invasive medical device market.

Nordson Corporation engineers, manufactures and markets differentiated products and systems used to dispense, apply and control adhesives, coatings, polymers, sealants, biomaterials, and other fluids, to test and inspect for quality, and to treat and cure surfaces. These products are supported by application expertise and direct global sales and service. Nordson serves a wide variety of consumer non-durable, durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in nearly 40 countries.

Oaklins' team in Ireland advised the seller in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

 Raymond  Donegan

Raymond Donegan

Director

Dublin, Ireland
Oaklins IBI
 Ailbhe  Doyle

Ailbhe Doyle

Senior Associate

Dublin, Ireland
Oaklins IBI

Related deals

Global Media Santé has been acquired by SFP Expansion
Private Equity | Healthcare | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Learn more
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Healthcare

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Learn more
Westminster Homecare has been acquired by Care at Home
Healthcare

Westminster Homecare has been acquired by Care at Home

The private shareholders of Westminster Homecare Ltd. have sold the company to Care at Home Services (South East) Ltd.

Learn more